Novasenta

Novasenta is a private, preclinical-stage biotech leveraging a unique, human tissue-centric discovery platform to identify novel therapeutic targets in the tumor microenvironment. The company's approach combines deep computational biology with experimental validation to build a pipeline of antibody-based therapies for cancer and immune disorders. Led by a team with strong industry experience in immunology and drug development, Novasenta aims to generate next-generation, safer, and more effective immunotherapies. As a pre-revenue company, its success hinges on validating its platform and advancing its internal pipeline toward clinical proof-of-concept.

Proprietary target discovery platform integrating single-cell analysis of high-quality human tissue samples with advanced computational data mining to identify novel, druggable targets in the tissue microenvironment, followed by in-house experimental validation and antibody development.

Novasenta competes in the crowded immuno-oncology and immunology space against large pharmaceutical companies and numerous biotechs. Its differentiation lies in its human tissue-centric, computational discovery engine, as opposed to platforms more reliant on murine models or known biology. Competitors range from platform companies like Recursion or Insitro to therapeutic developers like Arcus, Jounce (acquired), and many others targeting the tumor microenvironment.